

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt about the course of action to be taken, you should consult your stockbroker, bank manager, solicitor, accountant or other professional advisers immediately.

Bursa Malaysia Securities Berhad ("Bursa Securities") has perused this Circular in respect of the proposed new shareholders' mandate for Recurrent Related Party Transactions of a revenue or trading nature on a limited review basis pursuant to the provisions of the Practice Note 18 of the Main Market Listing Requirements of Bursa Securities.

Bursa Securities takes no responsibility for the contents of this Circular, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Circular.

OPTIMAX

New Vision New Life®

OPTIMAX HOLDINGS BERHAD

Registration No.: 201801028697 (1290723-T)

(Incorporated in Malaysia under the Companies Act 2016)

CIRCULAR TO SHAREHOLDERS

IN RELATION TO THE

PROPOSED RENEWAL OF EXISTING SHAREHOLDERS' MANDATE FOR RECURRENT RELATED PARTY TRANSACTIONS OF A REVENUE OR TRADING NATURE ("PROPOSED SHAREHOLDERS' MANDATE")

The resolution in respect of the Proposed Shareholders' Mandate will be tabled at Optimax Holdings Berhad's Seventh Annual General Meeting ("7th AGM") which will be held at Wira Ballroom, Level 2, Hyatt Place Kuala Lumpur, M-1, Pusat Perdagangan Bandar, Persiaran Jalil 1, Bukit Jalil, 57000 Kuala Lumpur on Monday, 8 June 2026 at 10.00 a.m.

The Notice of the 7th AGM together with the Proxy Form are set out in the Annual Report of Optimax Holdings Berhad for the financial year ended 31 December 2025 and also available at www.optimax.com.my

You are entitled to attend, speak and vote (collectively, "participate") at the 7th AGM or appoint a proxy(ies) to do so on your behalf. In such event, the Proxy Form should be completed and lodged at the Registered Office of the Company at Office Suite No. 603 Block C, Pusat Dagangan Phileo Damansara 1, No. 9, Jalan 16/11, Off Jalan Damansara, 46350 Petaling Jaya, Selangor or by electronic means via **Dvote Online** website at www.dvote.my, on or before the date and time indicated below or at any adjournment thereof for it to be valid.

The lodging of the Proxy Form does not preclude a member from attending and voting in person at the 7th AGM, should the member subsequently wish to do so and in such an event, the member's Proxy Form shall be deemed to have been revoked.

Last date and time for lodging the Proxy Form : Saturday, 6 June 2026 at 10.00 a.m.

Date and time of 7th AGM : Monday, 8 June 2026 at 10.00 a.m.

This Circular is dated 28 April 2026

DEFINITIONS

For the purposes of this Circular, except where the context otherwise requires, the following definitions shall apply:-

Act	: Companies Act 2016, as amended from time to time and any re-enactment thereof for the time being in force
AGM	: Annual General Meeting
ARMC	: Audit and Risk Management Committee of Optimax
Board	: Board of Directors of the Company
Bursa Depository	: Bursa Malaysia Depository Sdn. Bhd. [Registration No. 198701006854 (165570-W)]
Bursa Securities	: Bursa Malaysia Securities Berhad [Registration No. 200301033577 (635998-W)]
Circular	Circular to Shareholders in relation to the Proposed Shareholders' Mandate dated 28 April 2026
Constitution	: Constitution of the Company
Director	: Shall have the meaning given in Section 2(1) of the Capital Markets and Services Act 2007 and for the purposes of the Proposed Shareholders' Mandate, this includes any person who is or was within the preceding six (6) months of the date on which the terms of the transaction were agreed upon, a Director of the Company or any other company which is its subsidiary or holding company or a chief executive officer of the Company, its subsidiary or holding company
Interested Director	: A Director who is deemed to be a Related Party and is interested in the Proposed Shareholders' Mandate
Interested Major Shareholder	: A Major Shareholder who is deemed to be a Related Party and is interested in the Proposed Shareholders' Mandate
ITMAX System	: ITMAX System Berhad [Registration No. 200101008580 (544336-M)]
ITMAX System Group	: Collectively, ITMAX System and its subsidiaries
Listing Requirements	: The Main Market Listing Requirements of Bursa Securities, including any amendment(s) that may be made from time to time and any Practice Notes issued in relation thereto
LPD	: 2 April 2026, being the latest practicable date prior to the issuance of this Circular

DEFINITIONS

Major Shareholder(s)	: A person who is or was within the preceding six (6) months of the date on which the terms of the transaction were agreed upon, who has an interest or interests in one or more voting shares in Optimax, its subsidiary or holding company and the number or aggregate number of voting shares, is: (a) 10% or more of the total number of voting shares in Optimax; or (b) 5% or more of the total number of voting shares in Optimax where such person is the largest shareholder of Optimax. For the purpose of this definition, “interest” shall have the meaning of “interest in shares” given in Section 8 of the Act.
Michelle Tan	: Tan Sing Chia, Non-Independent Executive Director of Optimax
Modal Saujana	: Modal Saujana Sdn. Bhd., [Registration No. 199701017437 (432934- W)]
NA	: Net assets attributable to ordinary equity holders of our Company
NBV	: Net book value
Optimax or Company	: Optimax Holdings Berhad [Registration No. 201801028697 (1290723-T)]
Optimax Group or Group	: Collectively, Optimax and its subsidiaries
Optimax Share or Share	: Ordinary share in Optimax
Person(s) Connected	: Shall have the same meaning given in Paragraph 1.01 of the Listing Requirements
Proposed Shareholders’ Mandate	: Proposed renewal of existing shareholders’ mandate for RRPTs as set out in Section 2.4.1 of this Circular
Puan Sri Datin Lim	: Puan Sri Datin Lim Sho Hoo
Related Party or Related Party(ies)	: Director(s), major shareholder(s) or person(s) connected with such Director(s) or major shareholder(s) as envisaged in Paragraph 1.01 and Paragraph 10.02 of the Listing Requirements
RRPTs or Recurrent Transactions	: Recurrent related party transaction(s) of a revenue or trading nature, which are necessary for day-to-day operations and are in the ordinary course of business of Optimax Group which involve the interest, direct or indirect, of a Related Party(ies)
RM and sen	: Ringgit Malaysia and sen, respectively

DEFINITIONS

Rules of Bursa Depository	: The rules of Bursa Depository as issued pursuant to the SICDA
Sandy Tan	: Tan Sing Yee, Non-Independent Executive Director and Chief Executive Officer of Optimax
Sena Healthcare Services	: Sena Healthcare Services Sdn. Bhd. [Registration No. 201101009752 (937891-K)]
Sena Holdings	: Sena Holdings Sdn. Bhd. [Registration No. 199901012895 (487795- P)], a major shareholder of Optimax
Sena Letrik	: Sena Letrik (M) Sdn. Bhd. [Registration No. 198401003301 (115820- W)]
Sena Wellness	: Sena Wellness Sdn. Bhd. [Registration No. 201001038827 (922751- A)]
Physiomax	: Physiomax Sdn. Bhd. [Registration No. 202301038582 (1532504- P)]
Tan Sri Dato' (Dr.) Tan	: Tan Sri Dato' (Dr.) Tan Boon Hock, Non-Independent Executive Director and Deputy Chairman and a major shareholder of Optimax
Transacting Party(ies)	: A party with which Optimax Group has entered or may enter into a RRPT under the Proposed Shareholders' Mandate
William Tan	: Tan Wei Lun

Subsidiaries of Optimax

Beaumax	: Beaumax Sdn. Bhd. [Registration No. 202101029168 (1429468- P)] (80% interest held through OESC)
Inspirasi Alamjaya	: Inspirasi Alamjaya Sdn. Bhd. [Registration No. 201201043810 (1028287-D)] (100% interest held through OESC Southern)
JuiceMax Sdn. Bhd.	: JuiceMax Sdn. Bhd. (Formerly known as Optimax Eye Specialist Centre (Bukit Mertajam) Sdn. Bhd.) [Registration No. 202301007812 (1501733-U)] (100% interest held through OESC)
Nasenmax Sdn. Bhd.	: Nasenmax Sdn. Bhd. (Formerly known as Wellmax Sdn. Bhd.) [Registration No. 200801003710 (804994-H)] (100% interest held through OESC)
OESC	: Optimax Eye Specialist Centre Sdn. Bhd. [Registration No. 199501000582 (329776-D)] (wholly owned subsidiary of Optimax)
OESC Bahau	: Optimax Eye Specialist Centre (Bahau) Sdn. Bhd. [Registration No. 202101005834 (1406133-X)] (100% interest held through OESC)
OESC Bandar Sunway	: Optimax Eye Specialist Centre (Bandar Sunway) Sdn. Bhd. [Registration No. 200701036559 (794588-D)] (70% interest held through OESC)
OESC Ipoh	: Optimax Eye Specialist Centre (Ipoh) Sdn. Bhd. [Registration No. 200201029578 (597241-U)] (100% interest held through OESC)

DEFINITIONS

OESC Kluang	: Optimax Eye Specialist Centre (Kluang) Sdn. Bhd. [Registration No. 201701027461 (1241627-D)] (90% interest held through OESC Southern)
OESC Kuching	: Optimax Eye Specialist Centre (Kuching) Sdn. Bhd. [Registration No. 200701039589 (797621-V)] (100% interest held through OESC)
OESC Muar	: Optimax Eye Specialist Centre (Muar) Sdn. Bhd. [Registration No. 200601016753 (736505-T)] (100% interest held through OESC Southern)
OESC Shah Alam	: Optimax Eye Specialist Centre (Shah Alam) Sdn. Bhd. [Registration No. 200301021426 (623846-H)] (100% interest held through OESC)
OESC Segamat	: Optimax Eye Specialist Centre (Segamat) Sdn. Bhd. [Registration No. 201701027643 (1241809-M)] (90% interest held through OESC Southern)
OESC Seremban	: Optimax Eye Specialist Centre (Seremban) Sdn. Bhd. [Registration No. 200801014414 (815703-P)] (100% interest held through OESC)
OESC Seri Petaling	: Optimax Eye Specialist Centre (Seri Petaling) Sdn. Bhd. [Registration No. 200101022531 (558289-K)] (70% interest held through OESC)
OESC Southern	: Optimax Eye Specialist Centre (Southern) Sdn. Bhd. [Registration No. 201701016274 (1230438-H)] (70% interest held through OESC)
OESC Sutera	: Optimax Eye Specialist Centre (Sutera) Sdn. Bhd. [Registration No. 202101029171 (1429471-P)] (100% interest held through OESC Southern)
Optimax International	: Optimax International Sdn. Bhd. [Registration No. 202101011650 (1411949-U)] (100% interest held through OESC)
Optixanthin	: Optixanthin Sdn. Bhd. [Registration No. 201901022570 (1331899-X)] (100% interest held through OESC)

All references to “our Company” in this Circular are to Optimax and references to “our Group” are to our Company and subsidiaries collectively and references to “we”, “us”, “our”, and “ourselves” are to our Company, and save where the context otherwise requires, shall include our subsidiaries.

All references to “you” in this Circular are references to the shareholders of the Company.

Unless specifically referred to, words denoting the singular shall, where applicable, include the plural and vice versa and words denoting the masculine gender shall, where applicable, include the feminine and/or neuter gender, and vice versa. Reference to persons shall include corporations, unless otherwise specified.

Any reference to any legislation or guideline in this Circular is a reference to that legislation or guideline as amended or re-enacted from time to time.

Where applicable, values have been rounded to the nearest thousand.

Any reference to time of day in this Circular is a reference to Malaysian time, unless otherwise stated.

TABLE OF CONTENTS

LETTER TO THE SHAREHOLDERS IN RELATION TO THE PROPOSED SHAREHOLDERS' MANDATE CONTAINING:

SECTION	PAGE
1. INTRODUCTION	1
2. DETAILS OF THE PROPOSED SHAREHOLDERS' MANDATE.....	2
3. STATEMENT BY ARMC	21
4. DISCLOSURE OF RRPTS.....	22
5. RATIONALE AND BENEFITS OF THE PROPOSED SHAREHOLDERS' MANDATE	22
6. EFFECTS OF THE PROPOSED SHAREHOLDERS' MANDATE	22
7. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS	22
CONNECTED TO THEM	
8. APPROVALS REQUIRED.....	23
9. DIRECTORS' RECOMMENDATION	23
10. AGM	24
11. FURTHER INFORMATION	24

OPTIMAX

New Vision New Life®

OPTIMAX HOLDINGS BERHAD

Registration No.: 201801028697 (1290723-T)

(Incorporated in Malaysia under the Companies Act 2016)

Registered Office:

Office Suite No. 603 Block C
Pusat Dagangan Phileo Damansara 1
No. 9, Jalan 16/11
Off Jalan Damansara
46350 Petaling Jaya
Selangor

Date: 28 April 2026

Board of Directors:

Dato' Seri Dr. Chen Chaw Min
Tan Sri Dato' (Dr.) Tan Boon Hock
Tan Sing Yee

Independent Non-Executive Director and Chairman
Non-Independent Executive Director and Deputy Chairman
Non-Independent Executive Director and Chief Executive Officer

Tan Sri Dato' Seri Mohamad Noor bin Abdul Rahim
Tan Sing Chia
Yap Ping Hong
Mohd Sahir Bin Rahmat
Dr Zaiton Binti Nasir

Non-Independent Non-Executive Director

Non-Independent Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director

To: The Shareholders of Optimax

Dear Sir/Madam,

PROPOSED SHAREHOLDERS' MANDATE

1. INTRODUCTION

At the Company's Sixth AGM held on 10 June 2025, the Company obtained the shareholders' mandate for Optimax Group to enter into RRPTs as stipulated in the Circular to Shareholders dated 29 April 2025 which are necessary for the day-to-day operations of the Optimax Group with the Related Parties. The authority granted pursuant to the shareholder's mandate shall, in accordance with the Listing Requirements, expire at the conclusion of the forthcoming 7th AGM of the Company to be convened unless the authority is renewed.

On 24 April 2026, the Board announced its intention to seek its shareholders' approval for the Proposed Shareholders' Mandate pursuant to Paragraph 10.09 of Chapter 10 and Paragraph 3.1.4 of Practice Note 12 of the Listing Requirements at the forthcoming 7th AGM of the Company.

THE PURPOSE OF THIS CIRCULAR IS TO PROVIDE YOU WITH RELEVANT INFORMATION RELATING TO THE PROPOSED SHAREHOLDERS' MANDATE, TO SET OUT THE RECOMMENDATION BY THE BOARD THEREON AND TO SEEK YOUR APPROVAL FOR THE ORDINARY RESOLUTION PERTAINING TO THE PROPOSED SHAREHOLDERS' MANDATE TO BE TABLED AT THE FORTHCOMING 7TH AGM.

THE NOTICE OF THE 7TH AGM TOGETHER WITH THE PROXY FORM ARE ENCLOSED IN THE ANNUAL REPORT OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025 DESPATCHED TOGETHER WITH THIS CIRCULAR.

YOU ARE ADVISED TO READ AND CONSIDER THE CONTENTS OF THIS CIRCULAR CAREFULLY BEFORE VOTING ON THE RESOLUTION PERTAINING TO THE PROPOSED SHAREHOLDERS' MANDATE.

2. DETAILS OF THE PROPOSED SHAREHOLDERS' MANDATE

It is anticipated that in the normal course of the Group's business, Recurrent Transactions between Optimax Group and the Related Parties are likely to occur from time to time, and with some degree of frequency. In this respect, the Directors are seeking approval from the shareholders for the Proposed Shareholders' Mandate which will allow the Group to enter into Recurrent Transactions referred to in Section 2.4 with the Related Parties, provided such transactions are undertaken in the ordinary course of business and are on transaction prices and terms not more favourable to the Related Party(ies) than those generally available to the public and are not to the detriment of the minority shareholders of Optimax.

2.1 Provisions under the Listing Requirements

Pursuant to Paragraph 10.09(2) and Practice Note 12 of the Listing Requirements, the Company proposes to seek a general mandate from you for the RRPTs subject to, *inter-alia*, the following:

- (a) the RRPTs are in the ordinary course of business and are on terms not more favourable to the Related Party or Related Parties than those generally available to the public;
- (b) the shareholders' mandate is subject to annual renewal and disclosure is made in the annual report of the aggregate value of transactions conducted pursuant to the shareholders' mandate during the financial year where the aggregate value is equal to or more than the threshold below in relation to a listed issuer with a share capital of RM60 million and above:
 - (i) the consideration, value of the assets, capital outlay or costs of the RRPT is RM1 million or more; or
 - (ii) the percentage ratios of such RRPT is 1% or more,whichever is the higher;
- (c) this Circular to shareholders in relation to the Proposed Shareholders' Mandate includes the information as may be prescribed by Bursa Securities. The draft Circular must be submitted to Bursa Securities together with a checklist showing compliance with such information;
- (d) in a meeting to obtain shareholders' mandate, an interested Related Party must not vote on the resolution in approving the transactions and ensuring that Person(s) Connected with them abstain from voting on the resolution in respect of the transactions; and

- (e) the Company immediately announces to Bursa Securities when the actual value of a RRPT entered into by the Company, exceeds the estimated value of the RRPT disclosed in this Circular by 10% or more and must include the information as may be prescribed by Bursa Securities in its announcement.

Where your mandate has been procured pursuant to the above, the provisions of Paragraph 10.08 of the Listing Requirements in relation to related party transactions will not apply.

2.2 Validity Period of the Proposed Shareholders' Mandate

The authority to be conferred pursuant to the Proposed Shareholders' Mandate, if approved by the shareholders of the Company, shall take effect from the passing of the ordinary resolution to be proposed at the forthcoming 7th AGM and is subject to annual renewal. In this respect, the Proposed Shareholders' Mandate shall only continue to be in force until:

- (i) the conclusion of the next AGM of the Company, following this 7th AGM at which the Proposed Shareholders' Mandate was passed at which time it will lapse, unless by a resolution passed by the shareholders of the Company in a general meeting whereby the authority is renewed; or
- (ii) the expiration of the period within which the next AGM of the Company after that date is required to be held pursuant to Section 340(2) of the Act (but must not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); or
- (iii) revoked or varied by a resolution passed by the shareholders of the Company in a general meeting,

whichever is earlier.

2.3 Principal activities of Optimax Group

The principal activities of the Company is an investment holding company and principally provides specialist services supported by its network of 24 eye specialist centres and 1 aesthetic centre in Malaysia. The principal activities of the subsidiaries involved in the Recurrent Transactions are as follows:

<u>Subsidiaries</u>	<u>Principal Activities</u>	<u>Percentage of effective Interests</u>
Beamax	Activities of holding companies, specialised medical services & hospital activities	80%
Inspirasi Alamjaya	Eye specialist services and related products and services	100%
OESC	Eye specialist services and related products and services and investment holding	100%
OESC Bahau	Specialised medical services	100%
OESC Bandar Sunway	Eye specialist services and related products and services	70%
JuiceMax	Specialised medical services, food or beverage, food and beverage preparation in market stalls/ hawkers, retail sale of other food products n.e.c	100%

<u>Subsidiaries</u>	<u>Principal Activities</u>	<u>Percentage of effective Interests</u>
OESC Ipoh	Eye specialist services and related products and services and plastic surgery with aesthetic services as area of interest	100%
OESC Kluang	Eye specialist services and related products and services	90%
OESC Kuching	Eye specialist services and related products and services	100%
OESC Muar	Eye specialist services and related products and services	100%
OESC Shah Alam	Eye specialist services and related products and services	100%
OESC Segamat	Eye specialist services and related products and services	90%
OESC Seremban	Eye specialist services and related products and services	100%
OESC Seri Petaling	Eye specialist services and related products and services	70%
OESC Southern	Investment holding	70%
OESC Sutera	Specialised medical services	100%
Optimax International	Investment holding	100%
Optixanthin	Marketing of food products, stores specialised in retail sale of pharmaceuticals, medical and orthopaedic goods and stores specialised in retail sale of perfumery, cosmetic and toilet articles	100%
Nasenmax	Medical services related to ENT (Ear, Nose and Throat)	100%

[The rest of this page is intentionally left blank]

2.4 Details of RRPTs and the Related Parties

The details of the RRPTs entered into by Optimax Group with the Transacting Parties under the Proposed Shareholders' Mandate are as follows:-

2.4.1 Proposed Shareholders' Mandate

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(a)	Sena Letrik and OESC and its subsidiaries	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (1)(a) – (1)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	Medical fees received from and Sena Letrik for eye treatment services and other medical services provided to employees of Sena Letrik group of companies.	450	145	450

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(b)	ITMAX System and OESC and its subsidiaries	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (2)(a) – (2)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them</p>	Medical fees received from ITMAX System for eye treatment and other medical services provided to employees of ITMAX System group of companies.	200	14	200

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(c)	Modal Saujana and OESC/ OESC Ipoh/ OESC Bahau	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (3)(a) – (3)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	<p>Payment of rental to Modal Saujana (as landlord) by the following parties for renting of the following premises:</p> <ul style="list-style-type: none"> • OESC (as tenant) – No. 17, Jalan Bayu Tinggi 7, 41200 Klang, Selangor for use as eye specialist centre and storage: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 3,917 square feet. 	100	78	100

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
			<ul style="list-style-type: none"> • OESC Ipoh (as tenant) – No. 1, Jalan Dato' Khong Kam Tak, Off Jalan Tambun, 31400 Ipoh, Perak: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 3,985 square feet. 	270	220	330
			<ul style="list-style-type: none"> • OESC Bahau (as tenant) – No. 13 & 15, Jalan Seraya 1, Pusat Perniagaan Seraya, Bandar IOI, 72100 Bahau, Negeri Sembilan: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 7,036 square feet. 	150	98	150

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(d)	Inspirasi Alamjaya and Tan Boon Hock Holdings Sdn Bhd (199101004124) (214434-D) ("TBH Holdings")/ Puan Sri Datin Lim	Interested major shareholders <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan Interested Directors <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan Refer to Note (4)(a) – (4)(f) and Note (5)(a) – (5)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them.	Payment of rental by Inspirasi Alamjaya (as tenant) to the following parties for renting of the following premises: <ul style="list-style-type: none"> • TBH Holdings (as landlord) – 55, Jalan Cantik 6, Taman Pelangi Indah, 81800 Ulu Tiram, Johor for use as eye specialist centre and storage: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 5,355 square feet. 	100	78	100
			<ul style="list-style-type: none"> • Puan Sri Datin Lim (as landlord) – 53, Jalan Cantik 6, Taman Pelangi Indah, 81800 Ulu Tiram, Johor for use as eye specialist centre and storage: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 5,355 square feet. 	100	78	100

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(e)	Tan Sri Dato' (Dr.) Tan and Inspirasi Alamjaya	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (6)(a) – (6)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	<p>Payment of rental to Tan Sri Dato' (Dr.) Tan (as landlord) by the following parties for renting of the following premises:</p> <ul style="list-style-type: none"> • Inspirasi Alamjaya (as tenant) <ul style="list-style-type: none"> - Akademik Suite #L9-10, Block A, Jalan Mount Austin, 81100 Johor Bahru, Johor for use as staff accommodation: <ul style="list-style-type: none"> - Rental payable on monthly basis; - Tenancy agreement does not exceed 3 years; and - Area: 753 square feet. 	30	18	30
(f)	OESC and Dr. Nor Zainura binti Zainal	<p>Interested director</p> <ul style="list-style-type: none"> • Dr. Nor Zainura binti Zainal <p>Refer to Note (7) for details of her relationship with our Directors, major shareholders and/or persons connected with her.</p>	<p>Payment of consultancy fees by OESC to –</p> <ul style="list-style-type: none"> • Dr. Nor Zainura binti Zainal for provision of professional services in relation to her expertise as specialist doctor, such as:- <ul style="list-style-type: none"> - consulting medical condition of patient; and - performing eye treatments or surgeries. 	450	34	450

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(g)	OESC Shah Alam and Dr. Nor Zainura binti Zainal	<p>Interested director</p> <ul style="list-style-type: none"> • Dr. Nor Zainura binti Zainal <p>Refer to Note (7) for details of her relationship with our Directors, major shareholders and/or persons connected with her.</p>	<p>Payment of consultancy fees by OESC Shah Alam to –</p> <ul style="list-style-type: none"> • Dr. Nor Zainura binti Zainal for provision of professional services in relation to her expertise as specialist doctor, such as:- <ul style="list-style-type: none"> – consulting medical condition of patient; and – performing eye treatments or surgeries. 	1,300	562	1,300
(h)	Sena Wellness and Optixanthin	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan • Dr. Chung Soon Hee <p>Refer to Note (8)(a) – (8)(g) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	<p>Sale of inventories by Optixanthin to -</p> <ul style="list-style-type: none"> • Sena Wellness for Optixanthin food product, such as:- <ul style="list-style-type: none"> – Opti-C, virgin coconut oil with astaxanthin and phosphatidylserine; and – Opti-I, botanical beverage mix berries with astaxanthin extract and marigold flower extract. 	300	12	175

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(i)	Sena Wellness and OESC	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan • Dr. Chung Soon Hee <p>Refer to Note (8)(a) – (8)(g) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	<p>Sale of inventories by OESC to -</p> <ul style="list-style-type: none"> • Sena Wellness for medical inventories, such as:- <ul style="list-style-type: none"> – Personal Protective Equipment (PPEs); and – Emergency trolley kits/consumables. 	250	0	150

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(j)	Sena Wellness and OESC and its subsidiaries	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan • Dr. Chung Soon Hee <p>Refer to Note (8)(a) – (8)(g) for details of their relationship with our Directors, major shareholders and/or persons connected with them.</p>	<p>Medical fees provided to employees of OESC and its subsidiaries and paid to Sena Wellness for medical services such as:-</p> <ul style="list-style-type: none"> - general health screening; and - cardiology screening. 	120	0	80

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to the shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	*Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(k)	ITMAX System and OESC Kluang/ OESC Segamat	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (2)(a) – (2)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them</p>	<p>Payment of rental to ITMAX System (as landlord) by the following parties for renting of the following premises:</p> <ul style="list-style-type: none"> • OESC Kluang (as tenant) – No. 43 & 44, Jalan Haji Manan, 86000 Kluang, Johor for use as eye specialist centre and storage: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 6,516 square feet. 	200	147	200
			<ul style="list-style-type: none"> • OESC Segamat (as tenant) – No. 49B & 49C, Jalan Genuang, 85000 Segamat, Johor for use as eye specialist centre: <ul style="list-style-type: none"> – Rental payable on monthly basis; – Tenancy agreement does not exceed 3 years; and – Area: 2,640 square feet. 	150	117	150

* The estimated values of the RRPTs set out in the table above are for the period from the conclusion of the forthcoming 7th AGM of the Company until the conclusion of the next AGM of the Company based on the Group's budgeted figures for the said period and may be subject to changes. The aggregate or actual values of these transactions may or may not exceed the said amounts over the said period.

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to the shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	* Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(1)	ITMAX System and OESC and its subsidiaries	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (2)(a) – (2)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them</p>	<p>Payment of contract revenue to ITMAX System Group for subscription on video surveillance service and maintenance for:-</p> <ul style="list-style-type: none"> - 24 outlets including all the existing ambulatory care centres, satellite clinics/centres and specialist hospital under Optimax Group; - Covers installation and maintenance; - For a period of 5 years for each branch unless additional CCTVs are installed at the branch; and - Subscription fees:- <ul style="list-style-type: none"> i. For video surveillance and maintenance services, payable on a monthly basis; and ii. The monthly fee varies by branch as the monthly fee is calculated based on the number of CCTVs installed at each branch. 	500	0	500

* The estimated values of the RRPTs set out in the table above are for the period from the conclusion of the forthcoming 7th AGM of the Company until the conclusion of the next AGM of the Company based on the Group's budgeted figures for the said period and may be subject to changes. The aggregate or actual values of these transactions may or may not exceed the said amounts over the said period.

No.	Transacting parties	Related Party and Nature of relationship	Nature of transaction	Estimated value disclosed in the circular to shareholders dated 29 April 2025 RM'000	Actual value transacted from last AGM till LPD RM'000	#Estimated value from the date of the forthcoming 7 th AGM to the next AGM RM'000
(m)	Physiomax Sdn. Bhd.	<p>Interested major shareholders</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sena Holdings • Puan Sri Datin Lim • William Tan <p>Interested Directors</p> <ul style="list-style-type: none"> • Tan Sri Dato' (Dr.) Tan • Sandy Tan • Michelle Tan <p>Refer to Note (9)(a) – (9)(f) for details of their relationship with our Directors, major shareholders and/or persons connected with them</p>	Sale of inventories such as Opixanthin (food product) by Opixanthin to Physiomax Sdn. Bhd.	100	2	75

The estimated values of the RRPTs set out in the table above are for the period from the conclusion of the forthcoming 7th AGM of the Company until the conclusion of the next AGM of the Company based on the Group's budgeted figures for the said period and may be subject to changes. The aggregate or actual values of these transactions may or may not exceed the said amounts over the said period.

Notes:

(1) Sena Letrik

- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director and major shareholder of Sena Letrik.
- (b) Sena Holdings is our major shareholder, where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
- (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan, Michelle Tan and William Tan. She is also a director of Sena Letrik.
- (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Sena Letrik.
- (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Sena Letrik.
- (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.

(2) ITMAX System

- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director and major shareholder of ITMAX System.
- (b) Sena Holdings is our major shareholder where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
- (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan, Michelle Tan and William Tan.
- (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
- (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is a director of ITMAX System.
- (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. He is the managing director and chief executive officer, and major shareholder of ITMAX System.

(3) Modal Saujana

- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director and major shareholder of Modal Saujana.
- (b) Sena Holdings is our major shareholder, where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
- (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan, Michelle Tan and William Tan. She is also a director of Modal Saujana.
- (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Modal Saujana.
- (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also a director of Modal Saujana.
- (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.

- (4) TBH Holdings
- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director and major shareholder of TBH Holdings.
 - (b) Sena Holdings is our major shareholder, where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
 - (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan and Michelle Tan. She is also a director of TBH Holdings.
 - (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of TBH Holdings.
 - (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of TBH Holdings.
 - (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
- (5) Puan Sri Datin Lim
- (a) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan, Michelle Tan and William Tan.
 - (b) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder, and Puan Sri Datin Lim's spouse.
 - (c) Sena Holdings is our major shareholder where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
 - (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
 - (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
 - (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
- (6) Tan Sri Dato' (Dr.) Tan
- (a) Tan Sri Dato' (Dr.) Tan is our Director, major shareholder and a person connected with Sandy Tan and Michelle Tan.
 - (b) Sena Holdings is our major shareholder where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
 - (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan and Michelle Tan.
 - (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
 - (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
 - (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.

- (7) Dr. Nor Zainura binti Zainal is our director of OESC Shah Alam, being our wholly-owned subsidiary.
- (8) Sena Wellness
- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director of Sena Wellness and a major shareholder through his shareholdings in Sena Healthcare Services. Sena Wellness is a wholly-owned subsidiary of Sena Healthcare Services.
 - (b) Sena Holdings is our major shareholder where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
 - (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan, Michelle Tan and William Tan. She is also a director and shareholder of Sena Healthcare Services.
 - (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Sena Healthcare Services.
 - (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Sena Healthcare Services.
 - (f) Dr. Chung Soon Hee is our director of OESC Seremban, OESC Ipoh and Juicemax Sdn. Bhd., being our wholly-owned subsidiary. He is also a director of Sena Wellness.
 - (g) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.
- (9) Physiomax Sdn. Bhd.
- (a) Tan Sri Dato' (Dr.) Tan is our Director and major shareholder. He is also a director of Physiomax Sdn. Bhd. and major shareholder through his shareholdings in Sena Healthcare Services. Physiomax Sdn. Bhd. is 80% owned by Sena Healthcare Services.
 - (b) Sena Holdings is our major shareholder, where Tan Sri Dato' (Dr.) Tan and William Tan are also the directors and major shareholders.
 - (c) Puan Sri Datin Lim is a person connected with Tan Sri Dato' (Dr.) Tan, Sandy Tan and Michelle Tan. She is also a director and shareholder of Sena Healthcare Services.
 - (d) Sandy Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also an alternate director of Sena Healthcare Services.
 - (e) Michelle Tan is our Director and the daughter of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim. She is also a director of Physiomax Sdn. Bhd. and an alternate director of Sena Healthcare Services.
 - (f) William Tan is our major shareholder by virtue of his shareholdings in Sena Holdings and the son of Tan Sri Dato' (Dr.) Tan and Puan Sri Datin Lim.

2.5 Basis of estimates

The estimated transaction values for the RRPTs referred to in Section 2.4 of this Circular are based on:-

- (i) estimated prevailing prices, which are reasonably market-competitive; and
- (ii) the sums incurred or received over the past years for similar transactions.

The estimated transaction values were also projected based on the assumption that:-

- (i) the Group's usual levels of transaction;
- (ii) the Group's projected business volume; and
- (iii) the current level of operations would be maintained,

from the date of the forthcoming 7th AGM to the next AGM.

2.6 Threshold of authority

There are no specific thresholds for approval of RRPTs within the Group. All RRPTs are subject to the approval of the Board after being reviewed by ARMC. Where any Director has any interest (direct or indirect) in any RRPTs, such Director shall abstain from deliberation and voting on the matter. If it is determined that the guidelines and/or procedures stipulated in Section 2.9 of this Circular are inadequate, The Company will obtain a fresh shareholders' mandate and to ensure that:

- (a) RRPTs will be conducted on an arms' length basis and on normal commercial terms and transaction prices which are not more favourable to the Related Parties than those generally available to the public; and
- (b) such transaction will not be detriment to the minority shareholders of the Company.

2.7 Deviation from Mandate

The actual value of RRPTs did not exceed the estimated value as approved under the previous shareholders' mandate granted to the Company at the last AGM.

2.8 Amount due from Related Parties

As at LPD, there was no amount due or owing to Optimax Group by its Related Parties pursuant to the RRPTs disclosed in Section 2.4 of this Circular, which has exceeded the credit term granted as at 31 December 2025. As such, the disclosures as required under Paragraphs 16A and 16B in Annexure PN12-A of the Listing Requirements are not applicable.

2.9 Review procedures for RRPTs

To promote good corporate governance in the conduct of the Company's business, the Group has established a framework for evaluating potential conflicts of interest and disclosure obligations arising out of transactions and business arrangements between the Company and its Related Parties. The procedures in this framework ensure RRPTs are undertaken on an arm's length basis, on transaction prices and normal commercial terms which are not more favourable to the Related Parties than those generally available to the public, are not to the detriment of our minority shareholders and are in the best interest of the Company. The review procedures of the Company's RRPTs are as follows:-

- (i) The transaction price for the sale and purchase of products or services shall be determined based on the prevailing market rates/prices for the products or services, and on normal commercial terms, or otherwise in accordance with applicable industry norms, after taking into account the pricing, level of services, quality and delivery of the products.

- (ii) Records will be maintained by the Company to capture all RRPTs entered into pursuant to the Proposed Shareholders' Mandate to ensure that relevant approvals have been obtained and all RRPTs are compiled for review and approval by the ARMC and Board respectively.
- (iii) The ARMC has the responsibility for reviewing the RRPT procedures and guidelines and reporting the same to the Board.
- (iv) In the review of RRPTs, the ARMC may, as it deems fit, requests for additional information pertaining to the transactions from independent sources and advisers.
- (v) If during the annual review, the ARMC and Board are of the view that the review procedures and processes are no longer appropriate, adequate or sufficient to monitor, track and identify RRPTs as well as to ensure that the RRPTs are made on arm's length basis, on terms and transaction prices not more favourable to the Related Parties than those generally available to the public and are not to the detriment of the minority shareholders, the ARMC will recommend to the Board to revise the existing procedures and processes to ensure the Group has in place adequate procedures and processes at all times.
- (vi) At least 2 other contemporaneous transactions with unrelated third parties for similar products or services and/or quantities will be used as comparison, wherever possible, to determine whether the price and terms offered to or by the Related Parties are fair and reasonable and comparable to those offered to or by other unrelated third parties for the same or substantially similar type of products or services and/or quantities. In the event that a quotation or comparative pricing from unrelated third parties cannot be obtained, the transaction price will be based on the usual business practices of the Group to ensure that the RRPTs are not more favourable to the Related Party than those generally available to the public and are not to the detriment of the Company or our Group or to our minority shareholders.
- (vii) The Interested Director in the RRPTs must abstain from our Board's deliberation and voting on the relevant resolution(s) in respect of the RRPTs. The Interested Director must inform our Board, of the details of the nature and extent of his interest, including all matters in relation to the proposed RRPTs that he is aware or should reasonably be aware of, which is not in the best interest of the Company or our subsidiary, as the case may be.
- (viii) The Interested Major Shareholder or Person Connected to them must not vote at the general meeting on the resolution approving the RRPTs. It is the duty of the Interested Director and Interested Major Shareholder to ensure that Persons Connected to them abstain from voting on the resolution approving the RRPTs.

3. STATEMENT BY ARMC

The ARMC has seen and reviewed the procedures set out in Section 2.9 of this Circular and is of the view that the procedures and processes are:

- (i) sufficient to ensure that the RRPTs are undertaken based on normal commercial terms which are not more favourable to the transacting parties than those generally available to the public and are not to the detriment of the Company's minority shareholders; and
- (ii) adequate to monitor, track and identify RRPTs in a timely and orderly manner and that such procedures and processes are reviewed on an annual basis or whenever the need arises.

4. DISCLOSURE OF RRPTS

The breakdown of the aggregate value of RRPTs will be disclosed in the Company's annual report for the financial year during which the Proposed Shareholders' Mandate is in force in accordance with Paragraph 3.1.5 of Practice Note 12 of the Listing Requirements, providing amongst others, the following information:

- (a) the type of RRPT(s) made; and
- (b) the names of the Related Parties involved in each type of RRT(s) made and their relationship with Optimax Group.

If the actual value of a RRPT entered into by Optimax Group exceeds the estimated value of the RRPT disclosed in Section 2.4 this Circular by 10% or more, the Company will make immediate announcement to Bursa Securities which will include information as may be prescribed by Bursa Securities.

5. RATIONALE AND BENEFITS OF THE PROPOSED SHAREHOLDERS' MANDATE

The Proposed Shareholders' Mandate will enable Optimax Group to carry out RRPT(s) necessary for the Group's day-to-day operations, which are time sensitive in nature, and will eliminate the need to announce and convene separate general meetings (if applicable) from time to time to seek shareholders' mandate before entering into such RRPT(s). This will substantially reduce the expenses, time and other resources associated with the convening of general meetings on an ad hoc basis, improve administrative efficiency and allow financial and manpower resources to be channelled towards attaining other corporate objectives.

The RRPT(s) carried out within the Optimax Group creates mutual benefits for the companies within the Group, such as expediency and increased efficiency necessary for day-to-day operations.

In addition, the RRPT(s) are intended to meet the business needs of the Group on the best possible terms. By transacting with the Related Parties, the Group would have an advantage of familiarity with the background and management of the Related Parties, thus enabling more informed commercial decisions to be made. In most dealings with the Related Parties, the Group and the Related Parties have close co-operation and a good understanding of each other's business needs thus providing a platform where all parties can benefit from conducting the RRPT(s).

6. EFFECTS OF THE PROPOSED SHAREHOLDERS' MANDATE

The Proposed Shareholders' Mandate will not have any effect on the issued and paid-up share capital of the Company and the substantial shareholders' shareholdings and is not expected to have a material effect on the NA per Share, gearing and earnings per Share of the Group.

The Proposed Shareholders' Mandate is in relation to the transactions which are of revenue or trading nature which forms part of the Group's day-to-day operations. Thus, those transactions will contribute positively to the Group's financial performance.

7. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED TO THEM

As at LPD, the direct and indirect interests of the Directors, Major Shareholders and/or Persons Connected to the Directors and Major Shareholders of Optimax who are interested and/or do not consider themselves independent in the RRPT(s) are as follows:

Name	As at the LPD			
	Direct		Indirect	
	No. of Shares	%	No. of Shares	%
<u>Interested Directors</u>				
Tan Sri Dato' (Dr.) Tan	147,786,000	27.20	166,358,100 ⁽¹⁾	30.62
Sandy Tan	2,060,000	0.38	-	-
Michelle Tan	2,060,000	0.38	-	-
<u>Interested Major Shareholders</u>				
Sena Holdings	161,526,100	29.73	-	-
William Tan	-	-	161,526,100 ⁽²⁾	29.73
<u>Person Connected</u>				
Puan Sri Datin Lim	712,000	0.13	151,906,000 ⁽³⁾	27.96
<u>Directors of subsidiaries</u>				
Dr. Chung Soon Hee	30,720,000	5.65	-	-
Dr. Nor Zainura binti Zainal	-	-	-	-

Note:

- (1) Deemed interested by virtue of Section 8 of the Companies Act, 2016 ("the Act") through a shareholding of more than 20% in Sena Holdings and held through his spouse and children.
- (2) Deemed interested by virtue of Section 8 of the Act through a shareholding of more than 20% in Sena Holdings.
- (3) Deemed interested by virtue of the interests held through her spouse and children.

Accordingly, the Interested Directors have abstained and will continue to abstain from all Board deliberations and voting on the Proposed Shareholders' Mandate. Further, the Interested Directors and Interested Major Shareholders will abstain from voting in respect of their direct and indirect interests, if any, on the resolution pertaining to the Proposed Shareholders' Mandate at the forthcoming 7th AGM.

In addition, the Interested Directors and Interested Major Shareholders have undertaken to ensure that the Persons Connected to them shall abstain from voting pertaining to the Proposed Shareholders' Mandate at the forthcoming 7th AGM in respect of their direct and indirect interests in the Company.

Save as disclosed above, none of the other Directors, Major Shareholders or Persons Connected to Directors or Major Shareholders of the Company has any interest, direct or indirect, in the Proposed Shareholders' Mandate.

8. APPROVALS REQUIRED

The Proposed Shareholders' Mandate is conditional upon the approval of the shareholders of the Company being obtained at the forthcoming 7th AGM.

9. DIRECTORS' RECOMMENDATION

The Directors of Optimax (save for Tan Sri Dato' (Dr.) Tan, Sandy Tan and Michelle Tan, who are the Interested Directors and have abstained from all deliberations and voting in respect of the Proposed Shareholders' Mandate) having considered all aspects of the Proposed Shareholders' Mandate and after careful deliberation, are of the opinion that the Proposed Shareholders' Mandate is in the best interest of the Company. Accordingly, the Board (save for Tan Sri Dato' (Dr.) Tan, Sandy Tan and Michelle Tan), recommends that you vote in favour of the ordinary resolution pertaining to the Proposed Shareholders' Mandate to be tabled at the forthcoming 7th AGM.

10. AGM

The ordinary resolution to approve the Proposed Shareholders' Mandate is set out in the Notice of the 7th AGM contained in the Company's Annual Report 2025.

You are entitled to attend and vote at the forthcoming 7th AGM or appoint a proxy(ies) to vote for and on your behalf. In the event if you are unable to attend and vote in person, you are requested to complete, sign and lodge the Proxy Form at the Registered Office of the Company at Office Suite No. 603 Block C, Pusat Dagangan Phileo Damansara 1, No. 9, Jalan 16/11, Off Jalan Damansara, 46350 Petaling Jaya, Selangor or by electronic means via Dvote Online website at <https://www.dvote.my>, not later than forty-eight (48) hours before the date and time fixed for the 7th AGM or at any adjournment thereof.

11. FURTHER INFORMATION

You are advised to refer to the attached Appendix I for further information.

Yours faithfully,
For and on behalf of the Board of Directors
OPTIMAX HOLDINGS BERHAD

DATO' SERI DR. CHEN CHAW MIN
Independent Non-Executive Director and Chairman

FURTHER INFORMATION**1. DIRECTORS' RESPONSIBILITY STATEMENT**

The Directors have seen and approved this Circular and they collectively and individually accept full responsibility for the accuracy of the information given and confirm that, after making all reasonable enquiries, to the best of their knowledge and belief, there are no other facts the omission of which would make any statement herein misleading.

2. MATERIAL CONTRACT

As at the LPD, there are no other material contracts (not being contracts entered into in the ordinary course of business) which have been entered into by the Group within two (2) years immediately preceding the date of this Circular.

3. MATERIAL LITIGATION, CLAIMS AND ARBITRATION

As at the LPD, the Group is not involved in any material litigation, claim or arbitration, either as plaintiff or defendant, and the Directors confirm that there is no legal proceeding, pending or threatened, against the Group or of any fact likely to give rise to any proceeding which might materially and adversely affect our business or financial position.

4. DOCUMENTS AVAILABLE FOR INSPECTION

The following documents are available for inspection by the shareholders at the Registered Office of Optimax at Office Suite No. 603 Block C, Pusat Dagangan Phileo Damansara 1, No. 9, Jalan 16/11, Off Jalan Damansara, 46350 Petaling Jaya, Selangor during normal office hours between Monday and Friday (except public holidays) from the date of this Circular to the date of the forthcoming 7th AGM:

- (a) The constitution of Optimax; and
- (b) The audited consolidated financial statements of Optimax for the past two (2) financial years ended 31 December 2024 and 31 December 2025.

[The remaining section of this page is intentionally left blank]